Baxter Hlthcare Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAXTER HLTHCARE, and when can generic versions of BAXTER HLTHCARE drugs launch?
BAXTER HLTHCARE has two hundred and eighteen approved drugs.
There are sixteen US patents protecting BAXTER HLTHCARE drugs. There are two tentative approvals on BAXTER HLTHCARE drugs.
There are thirty-seven patent family members on BAXTER HLTHCARE drugs in thirteen countries and three hundred and two supplementary protection certificates in sixteen countries.
Summary for Baxter Hlthcare
International Patents: | 37 |
US Patents: | 16 |
Tradenames: | 331 |
Ingredients: | 129 |
NDAs: | 218 |
Drugs and US Patents for Baxter Hlthcare
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baxter Hlthcare Corp | HALOPERIDOL | haloperidol lactate | INJECTABLE;INJECTION | 076828-001 | Aug 25, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Baxter Hlthcare | OSMITROL 15% IN WATER IN PLASTIC CONTAINER | mannitol | INJECTABLE;INJECTION | 013684-008 | Approved Prior to Jan 1, 1982 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Baxter Hlthcare Corp | MICAFUNGIN IN SODIUM CHLORIDE 0.9% | micafungin sodium | SOLUTION;INTRAVENOUS | 216142-002 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Baxter Hlthcare Corp | WYAMINE SULFATE | mephentermine sulfate | INJECTABLE;INJECTION | 008248-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Baxter Hlthcare
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Baxter Hlthcare Corp | DOXIL (LIPOSOMAL) | doxorubicin hydrochloride | INJECTABLE, LIPOSOMAL;INJECTION | 050718-002 | Jun 13, 2000 | 5,213,804 | ⤷ Sign Up |
Baxter Hlthcare | EXTRANEAL | icodextrin | SOLUTION;INTRAPERITONEAL | 021321-001 | Dec 20, 2002 | 6,248,726 | ⤷ Sign Up |
Baxter Hlthcare | BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-005 | Jan 27, 2003 | 4,593,119*PED | ⤷ Sign Up |
Baxter Hlthcare | NEXTERONE | amiodarone hydrochloride | INJECTABLE;INJECTION | 022325-002 | Nov 16, 2010 | 6,869,939 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BAXTER HLTHCARE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Inhalation | 99.90% | ➤ Subscribe | 2008-09-11 |
➤ Subscribe | Injection | 10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags | ➤ Subscribe | 2014-01-31 |
International Patents for Baxter Hlthcare Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 101959508 | ⤷ Sign Up |
Japan | 2017019879 | ⤷ Sign Up |
Canada | 3170514 | ⤷ Sign Up |
Brazil | 112022015170 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Baxter Hlthcare Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1586316 | 122011100019 | Germany | ⤷ Sign Up | PRODUCT NAME: BROMFENAC (2-AMINO-3-(4-BROMOBENZOYL)PHENYLESSIGSAEURE); REGISTRATION NO/DATE: EU/1/11/692/001 20110518 |
1429780 | SPC/GB12/058 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 |
1273292 | C01273292/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC 58751 28.05.2009 |
1255752 | C 2008 002 | Romania | ⤷ Sign Up | PRODUCT NAME: N-[2-(DIETILAMINO)ETIL]-5-[(Z)-(5-FLUORO-2-OXO-1,2-DIHIDRO-3H-INDOL-3-ILIDEN)METIL]-2,4-DIMETIL-1H-PIROL-3-CAROXAMIDA - SUNITINIB, OPTIONAL SUB FORMA UNEI SARI ACCEPTABILE FARMACEUTIC,INCLUSIV A SARII L-MALAT; NATIONAL AUTHORISATION NUMBER: RO EU/1/06/347/001, RO EU/1/06/347/002, RO EU/1/06/347/003; DATE OF NATIONAL AUTHORISATION: 20060719; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/06/347/001, EU/1/06/347/002, EU/1/06/347/003; DATE OF FIRST AUTHORISATION IN EEA: 20060719 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.